211 related articles for article (PubMed ID: 30298129)
1. Recent Progress in European Advanced Therapy Medicinal Products and Beyond.
Yu TTL; Gupta P; Ronfard V; Vertès AA; Bayon Y
Front Bioeng Biotechnol; 2018; 6():130. PubMed ID: 30298129
[TBL] [Abstract][Full Text] [Related]
2. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
3. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.
Ronfard V; Vertès AA; May MH; Dupraz A; van Dyke ME; Bayon Y
Tissue Eng Part B Rev; 2017 Apr; 23(2):199-210. PubMed ID: 27762892
[TBL] [Abstract][Full Text] [Related]
5. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.
Horgan D; Metspalu A; Ouillade MC; Athanasiou D; Pasi J; Adjali O; Harrison P; Hermans C; Codacci-Pisanelli G; Koeva J; Szucs T; Cursaru V; Belina I; Bernini C; Zhuang S; McMahon S; Toncheva D; Thum T
Biomed Hub; 2020; 5(3):130-152. PubMed ID: 33987187
[TBL] [Abstract][Full Text] [Related]
6. Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches.
O'Donnell BT; Ives CJ; Mohiuddin OA; Bunnell BA
Front Bioeng Biotechnol; 2019; 7():95. PubMed ID: 31134194
[TBL] [Abstract][Full Text] [Related]
7. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
[TBL] [Abstract][Full Text] [Related]
8. Innovative regenerative medicines in the EU: a better future in evidence?
Corbett MS; Webster A; Hawkins R; Woolacott N
BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
[TBL] [Abstract][Full Text] [Related]
9. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.
Jørgensen J; Hanna E; Kefalas P
J Mark Access Health Policy; 2020; 8(1):1715536. PubMed ID: 32082514
[No Abstract] [Full Text] [Related]
10. Creating conditions for the success of the French industrial advanced therapy sector.
Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
[TBL] [Abstract][Full Text] [Related]
11. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
Detela G; Lodge A
Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
[TBL] [Abstract][Full Text] [Related]
12. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
[TBL] [Abstract][Full Text] [Related]
13. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union.
Pellegrini G; Ardigò D; Milazzo G; Iotti G; Guatelli P; Pelosi D; De Luca M
Stem Cells Transl Med; 2018 Jan; 7(1):146-154. PubMed ID: 29280318
[TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
15. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
[No Abstract] [Full Text] [Related]
16. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
17. Does the development of new medicinal products in the European Union address global and regional health concerns?
Catalá-López F; García-Altés A; Alvarez-Martín E; Gènova-Maleras R; Morant-Ginestar C
Popul Health Metr; 2010 Dec; 8():34. PubMed ID: 21172012
[TBL] [Abstract][Full Text] [Related]
18. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
Bock AJ; Johnson D
Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
[TBL] [Abstract][Full Text] [Related]
19. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
20. Illustrative Potency Assay Examples from Approved Therapies.
Torrents S; Grau-Vorster M; Vives J
Adv Exp Med Biol; 2023; 1420():139-149. PubMed ID: 37258788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
